Valeant Pharmaceuticals has extended the acquisition period for Allergan.
Valeant Pharmaceuticals International has extended the expiration of its exchange offer to acquire all of the outstanding shares of Allergan to 5:00 p.m., New York City time, on December 31, 2014.
The exchange offer was previously scheduled to expire at 5:00 p.m., New York City time today, Friday, August 15, 2014.
All other terms and conditions of the exchange offer remain unchanged.
The depositary of the exchange offer has advised that, as of 9:00 a.m., New York City time, on August 15, 2014, a total of approximately 12,509,606 shares of Allergan common stock were validly tendered and not properly withdrawn in the exchange offer.
For further deal information visit Current Agreements (subscription required)
Read: more on M&A deals in pharma, biotech, life science partnering deal news, insights and glossary
Report : Partnering Agreements with Valeant 2009-2014
Report: Pharma and Biotech M&A Trends 2009-2014
View: Current Partnering’s M&A Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Partnering activity – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Parnering activity – latest trends in big biotech deal making activity